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Welcome to the 17th Annual Scientific Conference of the
Society on NeuroImmune Pharmacology.
We are pleased to publish the abstracts from the 17th
Annual Conference of the Society on NeuroImmune
Pharmacology (SNIP) in the Journal of Neuroimmune
Pharmacology. This is the second year that the abstracts
from our conference are published in their entirety. We are
most pleased that Springer has agreed to continue providing
open access to these abstracts. On behalf of the SNIP, we
especially recognize the continued support of Dr. Howard
E. Gendelman and Ms. Robin Taylor, the editor‐in‐chief
and managing editor, respectively, of the Journal of
Neuroimmune Pharmacology, and Ann Avouris, Springer
US, in seeing this abstract book to fruition.
Thegoalofthe2011SNIPConference—April5–10,2011,
at the Hilton Clearwater Beach Resort, Clearwater Beach, FL,
USA—will be to assess the role of drugs of abuse in
modulating neuroimmune responses and to elucidate the
physiological consequences of such alterations in infectious
disease processes, such as HIV-1 infection, to garner
knowledge helpful in the development of therapeutics.
The society believes that young investigators are key tothe
continuation and expansion of our field of neuroimmune
pharmacology. Thus, we have dedicated four events in this
year’s conference to young scientists. The 17th SNIP
Conference will open on Wednesday evening (April 6) with
the Young Investigator Poster Session, which highlights
recent research accomplishments by young researchers. This
poster session will be followed by a special “Meet the
Mentors” dinner, attended by the young investigators who
are presenting their work at the conference as well as mentors
from academia, industry, and the National Institutes of Health
(NIH), who have influenced the field of neuroimmune
pharmacology. Larry Robinson, Ph.D., Provost at Seton Hall
University, will be the featured speaker at this dinner and will
give a lecture on the value of mentoring in promoting career
development of young investigators. In addition to the Young
Investigator Poster Session, a general poster session will also
be held on Thursday, April 7. The third event dedicated to
young investigators will be the Young Investigators’ Sympo-
sium, which willtakeplace onFriday, April8. The aim of this
symposium will be to highlight the work of three postdoctoral
and three predoctoral researchers selected by the Young
Investigator Travel Award Committee, from the pool of over
40 abstracts, based on their quality and research accomplish-
ments. The Bill Narayan Memorial Lecture, sponsored by Dr.
Gendelman in memory of his mentor, the late Dr. Bill
Narayan, will be the fourth event dedicated to young
investigators. This lecture, which will be given on Saturday,
April9,willemphasizetheessentialrolethatreciprocityplays
in the mentor–mentee relationship, and will serve as an
exampleoftheimportantroleofthementorintheprofessional
and intellectual growth of young investigators.
This year’s conference will include two plenary lectures.
On Thursday, April 7, Horace H. Loh, Ph.D. will present
the first conference plenary lecture on receptor engineering
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analgesic.” Dr. Loh’s lecture will set the tone for the
conference in that it will highlight the integration of
pharmacology into the neuroimmunology of health and
disease. Our second plenary lecture will be presented by
Steve Nelson, M.D. (Dean, Louisiana State University
School of Medicine) at the opening session on Saturday,
April 9. Dr. Nelson will describe the nexus between
alcohol, immunosuppression, and HIV-1 infection. His
presentation will highlight the relationship between sub-
stance addiction and HIV-1 neurocognitive deficits, and
will shed light on the impact of these disorders on stem cell
biology. This plenary lecture will set the stage for symposia
V, VI, and VII to follow.
There will be a total of seven symposia presented at the
conference. The first two symposia will address important
issues on drugs of abuse and neuroAIDS. Symposium I
entitled, “Neuroimmune Interactions—The New Frontier
for Drugs of Abuse and their Endogenous Ligands,”
organized by Martin Adler, Ph.D. and Toby Eisenstein,
Ph.D. (Temple University School of Medicine), will
concentrate on drugs of abuse and their endogenous ligand
interactions with the neuroimmune system. Toby Eisen-
stein, as the current society president, will open the
symposium session with a discussion on our current
understanding of the impact that drugs of abuse have on
the neuroimmune axis. Kevin Tracey, M.D. (Feinstein
Institute for Medical Research) will be the keynote speaker
and will talk on the role of cholinergic anti-inflammatory
pathways and innate immunity. Next, Lynn Kirby, Ph.D.
(Temple University School of Medicine) will report on the
propensity of chemokines to act as neuromodulators, and
finally, Virginia Sanders, Ph.D. (The Ohio State University
College of Medicine) will discuss the effects of the
sympathetic nervous system, catecholamines, and norepi-
nephrine on immune function through actions mediated by
adrenergic receptors.
Symposium II, organized by Guy Cabral, Ph.D. (Virginia
Commonwealth University School of Medicine) and Sabita
Roy, Ph.D. (University of Minnesota), will focus on the
modulation of the peripheral immune system by drugs of
abuse and HIV-1. The symposium keynote speaker will be
Satya Dandekar, Ph.D. (University of California at Davis),
who will talk on the gut, germs, and HIV pathogenesis of
immune and neurological diseases. Lena Al-Harthi, Ph.D.
(Rush University Medical Center) will follow with a
presentation on the role of T cell activation and T cell
subsets in anti-HIV immunity. Tom Molitor, Ph.D. (Uni-
versity of Minnesota) will then address the effects of drug
abuse on maternal immunity and its influence on neonatal
immune development. Two young investigators will also
speak at this symposium. Honghong Yao, Ph.D. (University
of Nebraska Medical Center) will address the implications
of increased vascular permeability on the induction of
platelet-derived growth factor mediated by cocaine, and Li
Liu, Ph.D. (University of Hong Kong, SAR, People’s
Republic of China) will address the effects of the
cannabinoid, delta-9-tetrahydrocannabinol, on SIVmac251
infection in Chinese Macaque monkeys. The inclusion of
Drs. Yao and Liu in this symposium is intended to
encourage junior investigators to give oral presentations at
major symposia, and is in keeping with the mission of the
society to promote the professional development of young
investigators.
These first two symposia will be followed by a special
session that will focus on teaching and learning in the field
of Neuroimmune Pharmacology. This special session will
be co-chaired by Thomas J. Rogers, Ph.D. (Temple
University School of Medicine) and Tom Molitor, Ph.D.
(University of Minnesota College of Veterinary Medicine),
and will include invited talks on the topic as well as a
presentation by Howard E. Gendelman, M.D. (University
of Nebraska Medical Center) on “Video Research Coming
of Age.”
Symposia III and IV will encompass current therapeutic
approaches to managing neuropsychiatric and neurodegen-
erative disorders stemming from AIDS and drugs of abuse.
Symposium III, organized by Jag Khalsa, Ph.D. [National
Institute on Drug Abuse (NIDA)] and Michael Roth, M.D.
(UCLA), will be more clinical in nature and will address
neuropsychiatric complications of infectious diseases and
substances of abuse. Dave Thomas, M.D. (Johns Hopkins
University School of Medicine) will begin the symposium
with a presentation on the natural history of the HIV-1 and
hepatitis C (HCV) viruses. Glen Treisman, M.D. (Johns
Hopkins University School of Medicine) will then speak
about the management of neuropsychiatric complications of
infection, particularly HIV and HCV infections. The final
speaker of this symposium will be Sussana Naggie, M.D.
(Duke University School of Medicine), who will discuss
possible interventional agents for HIV and HCV.
Symposium IV has been organized by Abraham P.
Bautista, Ph.D. [National Institute on Alcohol Abuse and
Alcoholism (NIAAA)] and Jeymohan Joseph, Ph.D. [Na-
tional Institute of Mental Health (NIMH)]. A presentation
by Ru-Band Lu, M.D. (National Cheng Kong University,
Taiwan) will focus on genetic validation of the subtypes of
alcoholism. The role of neuroimmune signaling molecules
as related to the neuropathology of fetal alcohol spectrum
disorders then will be presented by Paul Drew, Ph.D.
(University of Arkansas). The focus of this symposium then
will broaden from alcohol-specific topics to therapeutic
strategies targeting neuroimmune modulation, and a dis-
cussion of therapeutic stem cell approaches to mitigate
brain inflammatory-derived neurodegenerative disorders.
These final two topics will be presented by Adron Harris,
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(University of Nebraska Medical Center), respectively.
Following this symposium, a luncheon NIH workshop
has been organized by David Shurtleff, Ph.D. (NIDA),
Jeymohan Joseph, Ph.D. (NIMH), and Abraham P. Bau-
tista, Ph.D. (NIAAA). This workshop will be presented by
officers from NIDA, NIMH, NIAAA, and the Office of the
Center of Scientific Review at NIH. Each of the NIH
presenters will share information on new program initia-
tives at NIH and provide insight on grant writing and the
grant review process.
The final three symposia will focus on the relationship
between substance addiction and HIV-1 neurocognitive
deficits, and will discuss the impact that these disorders has
on stem cell biology. Symposium V, “Cocaine and HIV-1
Interplay: Molecular Mechanisms of Action and Addiction,”
co-chaired by Norman Haughey, Ph.D. (Johns Hopkins
School of Medicine) and Michal Toborek, M.D., Ph.D.
(University of Kentucky School of Medicine), will focus on
theactionandaddictiverolesofcocaine.Thissymposiumwill
commence with a lecture by Tsung-Ping Su, Ph.D. (NIDA/
NIH) on molecular and inter‐organelle signaling in disease.
Other speakers in this symposium include John Wang, Ph.D.
(University of Missouri–Kansas School of Medicine), who
will speak on the molecular neurobiology of drug addiction,
Gayle Baldwin,Ph.D.(UCLA),whowilladdress the prosand
cons of mouse/human chimera models on the occurrence of
cocaine and HIV-1 co‐morbidity, and Avi Nath, M.D.
(National Institute of Neurological Disorders and Stroke),
who will present his work regarding fulminant encephalopa-
thy in HIV-infected cocaine users.
Following Symposium V, the Bill Narayan Memorial
lecture will be presented by Shilpa Buch, Ph.D. (University
of Nebraska Medical Center). David Volsky, Ph.D. (Co-
lumbia University School of Medicine) will introduce Dr.
Buch, who will talk on the interplay of HIV infection and
cocaine abuse in HIV-associated neurocognitive disorders.
Symposium VI, “HIV-Associated Neurocognitive Disor-
ders (HAND) and Drug Abuse,” will focus more specifically
on HAND and drug abuse. Co-chairs Linda Chang, M.D.
(University of Hawaii) and Mahendra Kumar, Ph.D. (Miller
School of Medicine, University of Miami) have selected Bob
Heaton, Ph.D. (University of California at San Diego) to give
the lecture on HAND in the pre-CART and CART eras.
Following this presentation, Eileen Martin, Ph.D. (University
of Illinois) will speak on NeuroAIDS and substance use
disorders, and Marilou Andres, Ph.D. (University of Hawaii)
will present her results on the effects of the APOE-epsilon4
allele on brain functioning and structure in HIV patients. The
final lecture of this symposium will be given by Valerie
Wojna, M.D. (University of Puerto Rico), who will discuss
challenges presented in the diagnosis of HAND in a group of
Hispanic, HIV-seropositive females.
The conference will conclude with symposium VII, “The
Consequences of Substance Abuse and HIV on Stem Cell
Biology.” Changhau Cui, Ph.D. (NIAAA/NIH) and Kurt
Hauser, Ph.D. (Virginia Commonwealth University School
of Medicine) have organized this symposium to include
lectures on the effects of opiates and alcohol on major brain
structures such as the CNS and hippocampus. The
presenters for this symposium will be Pamela Knapp, Ph.
D. (Virginia Commonwealth University School of Medi-
cine), Amelia Eisch, Ph.D. (UT Southwestern Medical
Center at Dallas), Ping Zhang, Ph.D. (Louisiana State
University Health Sciences Center), and Pankaj Seth, Ph.D.
(National Brain Research Centre, India).
In summary, the meeting will focus on disseminating
new knowledge in the convergent areas of neuroAIDS and
drug abuse, professional development of young investiga-
tors, active engagement of international investigators, and
integration of fundamental basic science concepts and their
clinical translation. The individual presentations range from
basic science topics, to studies involving animal models for
evaluation of infectious disease mechanisms and treatment
modalities, to the study of human populations (including
minority and female populations) and the effects of HIV in
those populations, and finally to the development of drugs
and other treatment modalities as a means of combating
HIV infection.
The Hilton Clearwater Beach Resort conference site is
conveniently located 20 min from the St. Petersburg/
Clearwater International Airport and a half hour from
Tampa International Airport, providing flexibility with
flights. Just steps away, the Clearwater Beach Marina offers
fishing, snorkeling, and dolphin-watching charters, and Pier
60 holds a nightly celebration in honor of the breathtaking
Gulf sunset. Restaurants and shops are a short walking
distance from the conference center.
Again, welcome to the 17th Annual Conference of the
Society on NeuroImmune Pharmacology.
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